Resiquimod

Phase 2Small molecule

GGraceway Pharmaceuticals, LLC

Resiquimod is one of 88 small molecule programs targeting Melanoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

Hepatitis BActive, not recruiting

InfluenzaActive, not recruiting

Common WartActive, not recruiting

MelanomaPhase 1

Active, not recruiting

Hepatitis BPhase 1/Phase 2

Active, not recruiting

InfluenzaPhase 1

Active, not recruiting

Common WartPhase 2

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Resiquimod

GGraceway Pharmaceuticals, LLC

Phase 2

1 2

Fluzone

GSK

Preclinical

37 3

Crestor

AstraZeneca

Preclinical

1 4

Trexall

Alnylam Pharmaceuticals

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 10

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Common Wart6 trials

Study With a Topical Gel to Treat Common Warts in Adults

Completed·GGraceway Pharmaceuticals, LLC·Phase 2·NCT00117923·88 enrolled

Study With a Topical Gel to Treat Common Warts in Adults

Completed·GGraceway Pharmaceuticals, LLC·Phase 2·NCT00117871·48 enrolled

An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

Completed·GGraceway Pharmaceuticals, LLC·Phase 2·NCT00116662·84 enrolled

Show 3 more trials

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

Completed·GGraceway Pharmaceuticals, LLC·Phase 2·NCT00116675·84 enrolled

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

Completed·GGraceway Pharmaceuticals, LLC·Phase 2·NCT00115141·88 enrolled

Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

Completed·GGraceway Pharmaceuticals, LLC·Phase 2·NCT00114920·88 enrolled

Melanoma2 trials

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

Completed·MMayo Clinic·Phase 1·NCT00470379·30 enrolled

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Completed·MMayo Clinic·Phase 1·NCT01748747·30 enrolled

Malignancies1 trial

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Completed·CCelldex Therapeutics·Phase 1/2·NCT00948961·70 enrolled

Influenza1 trial

Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists

Completed·UUniversity of British Columbia·Phase 1·NCT01737580·59 enrolled

Hepatitis B1 trial

Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator

Completed·UUniversity of British Columbia·Phase 1/2·NCT00175435·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Resiquimod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Resiquimod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Resiquimod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Graceway Pharmaceuticals, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGraceway Pharmaceuticals, LLC

Resiquimod

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Common Wart6 trials

Melanoma2 trials

Malignancies1 trial

Influenza1 trial

Hepatitis B1 trial

References

Drug Info

Quick Facts

Related News